Dear IPA members, Pompe patients, family members and GSD-net participants, The IPA board received several questions concerning participation in the

Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has granted marketing approval for Myozyme® (alglucosidase alfa)

Product is First Treatment for Pompe Disease Genzyme Corp. (Nasdaq: GENZ) announced today that it has received marketing authorization for

Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has extended by 90 days the review period

The IPA has developed the Pompe connections brochure to help get patients and their families timely and relevant information about